Immuno oncology News and Research

RSS

AbVitro launches PairMe Grant Challenge to provide access to AbPair technology

AbVitro Inc., an immuno-oncology discovery company, today announced access to its AbPairTM technology by launching the "PairMe Grant Challenge."

20 Aug 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ImmunoCellular Therapeutics, Ltd. announced today that it has reached agreement with the US Food and Drug Administration on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma.

13 Aug 2015

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Janssen Biotech, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson announced today an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies.

12 Aug 2015

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.

11 Aug 2015

CRI to honor three scientists for contributions to immunology and cancer immunotherapy research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunotherapy.

10 Aug 2015

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced today the winners of the 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research.

10 Aug 2015

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

6 Aug 2015

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.

28 Jul 2015

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.

15 Jul 2015

AnaptysBio announces completion of oversubscribed $40MM Series D financing round

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the completion of an oversubscribed $40MM Series D financing round.

15 Jul 2015

Sorrento, NantBioScience form joint venture to develop targeted therapies against cancer

Sorrento Therapeutics, Inc. and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today that they have established a joint venture to focus on the development of 'first-in-class' small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells.

9 Jul 2015

ImmunID announces publication of clinical study data on ImmunTraCkeR assay in the Journal for ImmunoTherapy of Cancer

ImmunID today announced the publication of a short report in the Journal for ImmunoTherapy of Cancer showing that the analysis of peripheral T cell receptor diversity using the company's ImmunTraCkeR assay is associated with clinical outcomes following Ipilimumab treatment in metastatic melanoma.

8 Jul 2015

ACCC launches new initiative to facilitate adoption of immuno-oncology in community cancer setting

The Association of Community Cancer Centers today launches the Institute for Clinical Immuno-Oncology, the first of its kind initiative aimed to rapidly facilitate the adoption of immuno-oncology in the community cancer setting.

8 Jul 2015

Pan Am Cancer Treatment Center announces publication of immuno-oncology text book

The Pan Am Cancer Treatment Center is pleased to announce the publication of a specialized textbook titled "Immuno-Oncology, from Bench to Bedside" which provides scientific rationale for the use of immunotherapy in the treatment of cancer.

25 Jun 2015

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

ImmunoCellular Therapeutics, Ltd. announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015.

22 Jun 2015

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.

16 Jun 2015

Ludwig Cancer Research announces opening of new branch in Lausanne, Switzerland

Ludwig Cancer Research announced today that it is opening a new Branch in Lausanne, Switzerland. The Branch will be focused primarily on applied cancer immunology and the design of novel molecular and cell-based immunotherapies. It will also develop technologies enabling the efficient, safe application of those therapies to as many patients as possible.

12 Jun 2015

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.

8 Jun 2015

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced an independent data monitoring committee (IDMC) has recommended the continuation of the company’s pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) following the first of three planned interim data analyses.

5 Jun 2015